WO1998047512A1 - 1,2,4-benzotriazine oxides formulations - Google Patents

1,2,4-benzotriazine oxides formulations Download PDF

Info

Publication number
WO1998047512A1
WO1998047512A1 PCT/US1998/007391 US9807391W WO9847512A1 WO 1998047512 A1 WO1998047512 A1 WO 1998047512A1 US 9807391 W US9807391 W US 9807391W WO 9847512 A1 WO9847512 A1 WO 9847512A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
hydrocarbyl
tirapazamine
alkoxy
pyrrolidino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/007391
Other languages
English (en)
French (fr)
Inventor
Stephen Brown
Edward Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Sanofi Pharmaceuticals Inc
Sanofi Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pharmaceuticals Inc, Sanofi Winthrop Inc filed Critical Sanofi Pharmaceuticals Inc
Priority to AU69690/98A priority Critical patent/AU6969098A/en
Priority to BR9808958-7A priority patent/BR9808958A/pt
Priority to CA002287257A priority patent/CA2287257C/en
Priority to DE69835167T priority patent/DE69835167T8/de
Priority to JP54612298A priority patent/JP2001523248A/ja
Priority to EP98915529A priority patent/EP1044005B1/en
Publication of WO1998047512A1 publication Critical patent/WO1998047512A1/en
Priority to NO19995109A priority patent/NO325275B1/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
PCT/US1998/007391 1997-04-21 1998-04-14 1,2,4-benzotriazine oxides formulations Ceased WO1998047512A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU69690/98A AU6969098A (en) 1997-04-21 1998-04-14 1,2,4-benzotriazine oxides formulations
BR9808958-7A BR9808958A (pt) 1997-04-21 1998-04-14 Formulações de óxidos de 1,2,4-benzotriazina
CA002287257A CA2287257C (en) 1997-04-21 1998-04-14 1,2,4-benzotriazine oxides formulations
DE69835167T DE69835167T8 (de) 1997-04-21 1998-04-14 1,2,4-benzotriazin-oxide enthaltende zubereitungen
JP54612298A JP2001523248A (ja) 1997-04-21 1998-04-14 １，２，４−ベンゾトリアジンオキシド配合物
EP98915529A EP1044005B1 (en) 1997-04-21 1998-04-14 1,2,4-benzotriazine oxides formulations
NO19995109A NO325275B1 (no) 1997-04-21 1999-10-20 Vandige formuleringer for behandling av krefttumorer samt anvendelse derav.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/837,637 1997-04-21
US08/837,637 US5827850A (en) 1995-09-25 1997-04-21 1,2,4-benzotriazine oxides formulations

Publications (1)

Publication Number Publication Date
WO1998047512A1 true WO1998047512A1 (en) 1998-10-29

Family

ID=25275027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/007391 Ceased WO1998047512A1 (en) 1997-04-21 1998-04-14 1,2,4-benzotriazine oxides formulations

Country Status (13)

Country Link
US (2) US5827850A (https=)
EP (1) EP1044005B1 (https=)
JP (1) JP2001523248A (https=)
AT (1) ATE332139T1 (https=)
AU (1) AU6969098A (https=)
BR (1) BR9808958A (https=)
CA (1) CA2287257C (https=)
DE (1) DE69835167T8 (https=)
DK (1) DK1044005T3 (https=)
ES (1) ES2267183T3 (https=)
NO (1) NO325275B1 (https=)
PT (1) PT1044005E (https=)
WO (1) WO1998047512A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624925A (en) * 1986-09-25 1997-04-29 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
NZ521436A (en) * 2002-09-17 2005-07-29 Auckland Uniservices Ltd DNA- targeted benzotriazine 1,4-dioxides and their use in cancer therapy
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
CA2456569A1 (en) * 2003-03-14 2004-09-14 Auckland Uniservices Limited Benzoazine mono-n-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
US7834178B2 (en) * 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
CN101683346B (zh) * 2008-09-24 2015-04-01 杭州民生药业有限公司 一种替拉扎明非肠道含水制剂及其制备方法
CN101683319B (zh) * 2008-09-24 2012-09-05 杭州民生药业有限公司 一种替拉扎明非肠道给药含水制剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001410A (en) * 1972-02-01 1977-01-04 Bayer Aktiengesellschaft 3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980779A (en) * 1972-02-01 1976-09-14 Bayer Aktiengesellschaft 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
DE69636837T2 (de) * 1995-09-25 2007-10-25 Sanofi-Aventis U.S. Llc 1,2,4-benzotriazinoxid-formulierungen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001410A (en) * 1972-02-01 1977-01-04 Bayer Aktiengesellschaft 3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same

Also Published As

Publication number Publication date
PT1044005E (pt) 2006-10-31
EP1044005A4 (en) 2001-08-08
ATE332139T1 (de) 2006-07-15
CA2287257A1 (en) 1998-10-29
DK1044005T3 (da) 2006-09-25
CA2287257C (en) 2007-06-12
EP1044005A1 (en) 2000-10-18
US5827850A (en) 1998-10-27
US6153610A (en) 2000-11-28
BR9808958A (pt) 2000-08-01
DE69835167T2 (de) 2007-06-06
ES2267183T3 (es) 2007-03-01
AU6969098A (en) 1998-11-13
EP1044005B1 (en) 2006-07-05
NO325275B1 (no) 2008-03-17
DE69835167T8 (de) 2007-12-06
DE69835167D1 (de) 2006-08-17
NO995109D0 (no) 1999-10-20
JP2001523248A (ja) 2001-11-20
NO995109L (no) 1999-12-21

Similar Documents

Publication Publication Date Title
EP2547333B1 (en) Stable bortezomib formulations
Sheldon et al. Radiosensitization of C3H mouse mammary tumours by a 2-nitroimidazole drug
US20040076679A1 (en) Gel delivery vehicles for anticellular proliferative agents
US6153610A (en) 1,2,4-benzotriazine oxides formulations
AU718268B2 (en) 1,2,4-benzotriazine oxides formulations
US12005066B2 (en) Cobinamide compounds as a cyanide, sulfide, or methane-thiol antidote
MXPA99009605A (en) 1,2,4-benzotriazine oxides formulations
TWI905111B (zh) 含有對硼苯基丙胺酸之注射液劑
MXPA98002314A (es) Formulaciones de oxidos de 1,2,4-benzotriazina
US20080039522A1 (en) Composition Containing a Complex Comprising a Metal Ion and a Carboxylate Ligand Having Anti-Inflammatory Activity
JPH0660097B2 (ja) 医薬用製剤
RU2618462C2 (ru) Способ и улучшенная фармацевтическая композиция для ускорения трансдермальной доставки ингибитора pde-5
RU2660353C2 (ru) Способ и улучшенная фармацевтическая композиция для ускорения трансдермальной доставки ингибитора pde-5
HK1016888A (en) 1,2,4-benzotriazine oxides formulations
CZ297199A3 (cs) Nevodný prostředek, nosič a kit pro léčení nemoci rozmnožujících se buněk

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE GW HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/009605

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2287257

Country of ref document: CA

Ref country code: CA

Ref document number: 2287257

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 546122

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998915529

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998915529

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1998915529

Country of ref document: EP